ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like Despite One Death and One Adverse Event, bluebird bio's Gene Therapy Study Meets Goals October 4, 2017 China-Based KB Biotech Solutions to Bring 100 New Jobs to South Carolina October 26, 2017 <b>Valbiotis</b>: Pascal SIRVENT Appointed Director Of Discovery And Preclinical Research September 14, 2017
Despite One Death and One Adverse Event, bluebird bio's Gene Therapy Study Meets Goals October 4, 2017
<b>Valbiotis</b>: Pascal SIRVENT Appointed Director Of Discovery And Preclinical Research September 14, 2017
